| Code | CSB-RA008545MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Nipocalimab-aahu, targeting the neonatal Fc receptor (FCGRT, FcRn). FCGRT plays a critical role in regulating IgG antibody homeostasis by binding to the Fc region of IgG molecules at acidic pH, protecting them from lysosomal degradation and extending their serum half-life. This receptor is expressed on various cell types including endothelial cells, epithelial cells, and immune cells, where it mediates bidirectional IgG transport across cellular barriers and maternal-fetal IgG transfer. Dysregulation of FCGRT-mediated IgG recycling is implicated in numerous autoimmune and alloantibody-mediated disorders, including myasthenia gravis, immune thrombocytopenia, hemolytic disease of the fetus and newborn, and other IgG-driven pathological conditions.
Nipocalimab-aahu represents a therapeutic antibody designed to block FCGRT function, thereby reducing pathogenic IgG levels. This biosimilar provides researchers with a valuable tool for investigating FCGRT biology, IgG catabolism mechanisms, and potential therapeutic strategies for autoimmune diseases. It supports studies exploring antibody recycling pathways, maternal-fetal immunity, and novel approaches to modulating humoral immune responses.
There are currently no reviews for this product.